ReviewJRSM cardiovascular disease2012
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues.
Review in JRSM cardiovascular disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review.The pharmacogenomics journal · 2022Pooled it
- Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review.Neuropsychology review · 2019Pooled it
- Pharmacogenetics of FSH Action in the Male.Frontiers in endocrinology · 2019Pooled it
- Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.Advances in therapy · 2016Pooled it
- Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.PloS one · 2016Pooled it
- A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.The international journal of neuropsychopharmacology · 2021Trial
- Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events.BMC medical genomics · 2026Article
- Drug-induced hepatotoxicity and association with slow acetylation variants NAT2*5 and NAT2*6 in Cameroonian patients with tuberculosis and HIV co-infection.BMC infectious diseases · 2024Article
- Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data.Clinical and translational science · 2024Review
- Application of Pharmacogenomics Testing in a Community-based Facility.Hospital pharmacy · 2023Article
- Promises and challenges in pharmacoepigenetics.Cambridge prisms. Precision medicine · 2023Review
- Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- From pharmacogenetics to pharmaco-omics: Milestones and future directions.HGG advances · 2022Review
- The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review.The pharmacogenomics journal · 2021Article
- Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.CPT: pharmacometrics & systems pharmacology · 2021Article
- Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice.Clinical and translational science · 2021Review
- Cost-effectiveness of precision medicine: a scoping review.International journal of public health · 2019Article
- Novel analytical methods to interpret large sequencing data from small sample sizes.Human genomics · 2019Article
- Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?Clinical pharmacology and therapeutics · 2019Article
- Medication Exposure Patterns in Primary Care Patients Prescribed Pharmacogenetically Actionable Opioids.Qualitative report (Online) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetics is the study of inherited variation in drug response. The goal of pharmacogenetics is to develop novel ways of maximizing drug efficacy and minimizing toxicity for individual patients. Personalized medicine has the potential to allow for a patient's genetic information to predict optimal dosage for a drug with a narrow therapeutic index, to select the most appropriate pharmacological agent for a given patient and to develop cost-effective treatments. Although there is supporting evidence in favour of pharmacogenetics, its adoption in clinical practice has been slow because of sometimes conflicting findings among studies. This failure to replicate findings may result from a lack of high-quality pharmacogenetic studies, as well as unresolved methodological and statistical issues. The objective of this review is to discuss the benefits of incorporating pharmacogenetics into clinical practice. We will also address outstanding methodological and statistical issues that may lead to heterogeneity among reported pharmacogenetic studies and how they may be addressed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.